ORIGINAL ARTICLE   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 April;177(4):113-6

DOI: 10.23736/S0393-3660.17.03616-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Effect of nutraceutical with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome

Nicola MARCHITTO ¹ ✉, Francesco SINDONA ², Alessandra FABRIZIO ³, Monica MAUTI ³, Simona ANDREOZZI ⁴, Serenella DALMASO ¹, Gianfranco RAIMONDI ⁵

¹ Alfredo Fiorini Hospital, Terracina, Latina, Italy; ² Faculty of Internal Medicine, “Sapienza” University of Rome, Rome, Italy; ³ Department of Nursing Sciences, “Sapienza” University of Rome, Rome, Italy; ⁴ Faculty of Medicine and Surgery, “Sapienza” University of Rome, Rome, Italy; ⁵ Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Internal Medicine, “Sapienza” University of Rome, Rome, Italy

BACKGROUND: The metabolic syndrome is a frequent risk factor for cardiovascular diseases and type 2 diabetes and consist of different metabolic disorders like central obesity, insulin resistance, hypertension and dyslipidemia associated to high value of triglycerides (TG) and low level of high-density lipoprotein (HDL). The prevalence of metabolic syndrome increases with age, degree of obesity and propensity to type 2 diabetes. The aim of this study was to evaluate the effect of nutraceutical with policosanol, berberina, red yeast rise, cassia nomame, astaxantina, Q10 coenzime and folic acid in patients with low to moderate dyslipidemia, intolerance to statins and metabolic syndrome.
METHODS: We have enrolled 30 patients (15 males and 15 females with range age 19-90 years, mean 71±19 years) that satisfying the NCEP:ATPIII 2001 Criteria for Metabolic Syndrome. Only 27 patients have completed all the protocol phases. All compliant patients were underwent to the evaluation of total cholesterol (t-chol), low-density lipoprotein (LDL), HDL, TG, heart rate variability, T-peak to T-end Index, QTc value and T-peak-end/QTc ratio, and side effects before and postadministration of standard treatment with policosanol, berberina, red yeast rise, cassia nomane, astaxantina, Q10 coenzime and folic acid.
RESULTS: Our study have shown a statistically significant change in t-chol (23033 mg vs. 180 mg±44 mg with P<0.001), low-density of lipoprotein (155±44 mg vs. 116±42 mg with P<0.001), HDL (43±18 mg vs. 49±18 mg with P<0.024) and TG (141±71 mg vs. 124±70 mg with P<0.012) with statistically significant correlation. Our data did not shown a statistically significant difference in the heart rate variability (P=0.978), SDNN (P=0.954), PNN (P=0.784), LF (P=0.990), HF (P=0.952), LF/HF Index (P=0.842), T-peak to T-end (P=0.741), QTc (P=0.689) and T-peak to T-end/QTc ratio (P=0.542).
CONCLUSIONS: Nutraceutical could be a new useful approach in the treatment of patients with Metabolic Syndrome and low or moderate dyslipidemia with intolerance to statins and not responsive to non-pharmacological treatment (lifestyle, diet, behavior modification and physical activity). Our preliminary data gives comfortable results.

KEY WORDS: Dyslipidemias - Metabolic syndrome X - Dietary supplements - Aged - Heart rate